DRI Healthcare Trust (TSE:DHT.UN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

DRI Healthcare Trust (TSE:DHT.UN) has received an average recommendation of “Moderate Buy” from the six research firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is C$18.00.

Several equities research analysts have recently issued reports on DHT.UN shares. Raymond James lowered their price target on DRI Healthcare Trust from C$23.00 to C$22.00 in a research report on Wednesday, November 13th. Scotiabank boosted their price target on shares of DRI Healthcare Trust from C$21.00 to C$22.00 and gave the company an “outperform” rating in a report on Tuesday, October 8th.

DRI Healthcare Trust Trading Up 43.1 %

Shares of TSE:DHT.UN opened at C$13.09 on Thursday. The firm has a fifty day moving average price of C$13.41 and a 200 day moving average price of C$13.35. DRI Healthcare Trust has a 1 year low of C$10.39 and a 1 year high of C$17.43.

DRI Healthcare Trust Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 18th. Investors of record on Friday, October 18th were given a $0.085 dividend. The ex-dividend date of this dividend was Friday, September 27th. This represents a $0.34 dividend on an annualized basis and a yield of 2.60%. DRI Healthcare Trust’s payout ratio is -920.00%.

About DRI Healthcare Trust

DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.